OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule
Executive Summary
Financial model isn't adequate currently, FDA Commissioner Robert Califf says, and agency may make regulatory changes to motivate sponsors.
You may also be interested in...
US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More
Califf was candid during Science Board meeting about agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.
US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before
Sponsors would be required to furnish patients with pre-paid envelopes to mail back unused opioid medications for disposal. Comments on FDA's proposal could follow industry concerns about burden on health care system voiced when the idea was floated in 2018.
Califf Says Opioid Labeling Changes, Withdrawals Still Possible
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.